ABSTRACT
BACKGROUND: Docetaxel is a chemotherapeutic agent of the taxane class of drugs for the treatment of breast cancer. We present a female patient who noted decreased vision after docetaxel treatment. CASE PRESENTATION: A 45-year-old female patient received docetaxel treatment after resection of a breast carcinoma. Funduscopy and optical coherence tomography (OCT) showed cystoid macular edema on both eyes. Dilated funduscopy also showed bone spicule-like pigmented deposits, typical for retinitis pigmentosa. Besides the fundus appearance restricted peripheral vision and scotopic electroretinogram confirmed the diagnosis of retinitis pigmentosa. Chemotherapy was discontinued following a consulation with the oncologist of the patient. After five weeks, visual acuity improved significantly along with decrease of retinal thickness measured by OCT. CONCLUSION: Docetaxel may cause ocular adverse effects such as cystoid macular edema. Ophthalmological examination is warranted for patients with visual complaints during docetaxel chemotherapy.
Subject(s)
Breast Neoplasms/drug therapy , Macular Edema/chemically induced , Retinitis Pigmentosa/complications , Taxoids/adverse effects , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Docetaxel , Dose-Response Relationship, Drug , Electroretinography , Female , Fluorescein Angiography , Fundus Oculi , Humans , Macular Edema/complications , Macular Edema/diagnosis , Middle Aged , Retinitis Pigmentosa/diagnosis , Taxoids/administration & dosage , Tomography, Optical Coherence , Visual AcuityABSTRACT
UNLABELLED: Authors presented data of treatment results and course of disease in 487 ovarian cancer patients treated by primary surgery and paclitaxel-carboplatin combination chemotherapy between July 1, 2002 and December 31, 2003. PATIENTS: Most of our patients (87.8%) belonged to the age-group between 40-70 years. Distribution of their histological diagnosis was as 69.6% serous, 10.7% mucinous, 5.1% endometrial and 4.7% undifferentiated carcinoma. The grade distribution was found as 8.4% grade 1, 40.9% grade 2 and 35.9% grade 3. RESULTS: The primary surgery was evaluated as optimal in 41.7%, suboptimal in 37.3% and exploration was performed in 21.1%. Most patients started chemotherapy 20 days after surgery and 74.2% of them got six courses. During the evaluation period 61 intervallum laparotomies were performed, and resulted on 55.7% optimal debulking. Complete remission was found in 58.9%, and partial remission in 14.7% of patients. This treatment resulted on a complete remission in 40.9% at the follow-up of 12 months.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma/therapy , Ovarian Neoplasms/therapy , Ovariectomy , Adenocarcinoma, Mucinous/therapy , Adult , Aged , Brenner Tumor/therapy , Carboplatin/administration & dosage , Carcinoma/drug therapy , Carcinoma/epidemiology , Carcinoma/pathology , Carcinoma/surgery , Carcinoma, Endometrioid/therapy , Chemotherapy, Adjuvant , Cystadenocarcinoma, Serous/therapy , Drug Administration Schedule , Female , Humans , Hungary/epidemiology , Middle Aged , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/epidemiology , Ovarian Neoplasms/pathology , Ovarian Neoplasms/surgery , Paclitaxel/administration & dosage , Retrospective Studies , Treatment OutcomeABSTRACT
Data on the first-line treatment of ovarian cancer in special centers of Hungary 2002 and 2003 are presented, involving 283 and 416 patients, respectively. Patients' age, clinical stage and histological type of the tumor were highly similar to literature data, while grades were different. Surgical effectiveness in case of IIIc staged tumors with >1 cm residual mass was 37%. The ratio of interval laparotomy was about 15%. Overall response rates of the first-line treatment of ovarian cancer was 82%, while the rate of complete remissions was 60%. The authors provide detailed analysis of factors that can improve the chemotherapy of ovarian cancer in Hungary.
